IRIC - Institute for Research in Immunology and Cancer

Published on June 26, 2013

HMR becomes IRICoR second academic member

IRICoR  (Institute for Research in Immunology and Cancer – Commercialization of Research) is proud to announce that Hôpital Maisonneuve-Rosemont (HMR) has recently become an Academic Member of the Centre, which represents the achievement of an official alliance between the two entities. Through this agreement, HMR becomes IRICoR’s second academic member after Université de Montréal (UdeM).
“Through the Centres of Excellence for Commercialization and Research (CECR) program funded by the Federal Government, Université de Montréal launched a key cutting-edge initiative in Drug Discovery by creating IRICoR in 2007”, says Dr Joseph Hubert Vice-Rector of Major Academic Projects.
“Since IRICoR’s early years, HMR has always been a  key affiliate both for its status as a reference center in Hematology-Oncology and for a number of its Clinical Researchers who are also Principal Investigators and Associate Investigators of the Institute for Research in Immunology and Cancer (IRIC) at UdeM”, says Dr Michel Bouvier, President and Chief Executive Officer at IRICoR.
“We welcome this official alliance between HMR and IRICoR with great enthousiasm”, says Mrs Manon Boily, Chief Executive Officer of HMR. Mrs Boily continues “our value chains will undoubtedly continue to be complementary in as much as HMR is already closely collaborating with UdeM/IRIC/IRICoR for the development of novel therapies in Leukemia through our Centre of Excellence for Cellular Therapy (CETC)”.